CA - The Prognosis For Pfizer

2024-05-22 16:29:53 ET

Summary

• Today, we take a more in-depth look at drug giant Pfizer Inc., which has experienced falling revenues as Covid-19 has become endemic.
• The acquisition of Seagen did add blockbuster oncology therapies to Pfizer's portfolio, boosting sagging oncology sales.
• Pfizer plans to launch new therapies and expand its oncology pipeline, aiming to generate $45 billion in revenue by 2030.
• With a low P/E compared to the overall market and a near six percent dividend yield, Pfizer merited a deeper dive.
• An analysis of the drug behemoth follows in the paragraphs below.

Not really needing any introduction, Pfizer Inc. ( PFE ) is a New York City-based biopharmaceutical behemoth that generated revenues of more than $240 billion in 2021-2023, primarily from vaccines and cancer medicines, which are sold in more than 200 countries across the planet. The December 2023 $43 billion acquisition of Seagen added at least two soon-to-be blockbuster products to the nine it marketed in 2023. That acquisition brought the company's clinical program total (as of January 30, 2024) to 112. Pfizer was established 175 years ago in 1849 and went public in 1942. Shares of PFE trade just over $28.50 a share, after putting in an 11-year low in April. The stock has just over a $160 billion market cap, and the options against the equity are extremely liquid....

For further details see: